MorphoSys in a nutshell

For patients

Antibodies are used as therapeutic agents for the treatment of severe diseases and MorphoSys contributes to the development of novel and improved approaches. The Company has both the technical and scientific skills that are needed for the generation of optimized antibodies as therapeutics. Together with its partners from the pharmaceutical industry, MorphoSys uses this expertise to develop the medicines of tomorrow. The Company’s development activities include, but are not limited to indications such as cancer, inflammations and autoimmune diseases.

Only the most promising of MorphoSys’s own and partnered drug development programs reach clinical trials, where they are thoroughly evaluated with regards to their quality, safety and efficacy. Amongst these programs are highly promising compounds in late clinical stages which could enter the market within the next few years.

For partners

Together with its partners from the pharmaceutical industry, MorphoSys is working on novel therapeutic approaches for severe diseases. The success of its partnerships is reflected by the variety of antibodies in development. Formerly, the Company’s technologies were paramount in forming the basis for partnering agreements. Today, alliances take several different forms. In order to further strengthen its existing portfolio, MorphoSys is constantly evaluating promising antibodies and other biomolecules at late preclinical or early clinical stages for in-licensing or co-development. Agreements on synergistic technologies add to the sustainable development of MorphoSys’s business.